"The launch of Enstilar® foam spray in the UK is a significant advance which provides an easy to apply topical combination treatment for plaque psoriasis, a distressing condition which affects up to 2 ...

Licence marks first combination foam spray for plaque psoriasis: Enstilar ® (calcipotriol/betamethasone dipropionate) 50 micrograms/g + 0.5mg/g cutaneous foam LEO ...

LEO Pharma has received scientific approval for Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris ...

A FOAM spray has been launched to help treat people with plaque psoriasis, a chronic, inflammatory skin condition which affects thousands of people in the UK. LEO Pharma has launched Enstilar, billing ...

A simple-to-use spray-on foam that quickly vanishes into the skin is the latest weapon in the battle against the debilitating skin condition psoriasis. Clinical trials into the newly licensed ...

Trials show that the foam, called Enstilar, is more effective than traditional creams and ointments. More than half of trial patients with the skin condition are said to have experienced significant ...

FOR DISTRIBUTION TO UK CONSUMER MEDIA ONLY (EXCLUDING REPUBLIC OF IRELAND AND MEDICAL MEDIA) Adherence is a significant challenge for patients living with psoriasis (studies consistently suggest that ...

"Due to the innovative foam spray delivery, Enstilar® is easy-to-apply and a offers a convenient, effective and generally well-tolerated new treatment option for people living with plaque psoriasis in ...